파마 4.0 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 기술별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Pharma 4.0 Market Summary

The global pharma 4.0 market size was estimated at USD 15.0 billion in 2025, and is projected to reach USD 61.7 billion by 2033, growing at a CAGR of 19.5% from 2026 to 2033. Pharma 4.0 represents a paradigm shift in pharmaceutical manufacturing through the integration of innovative technologies such as the Internet of Things (IoT), artificial intelligence (AI), big data analytics, and blockchain. These advancements are vital in enhancing and optimizing manufacturing processes within the industry.

The market's expansion is driven by several key drivers, including the rising demand for personalized medicine, the need for increased efficiency and productivity, and the pursuit of improved regulatory compliance. The growing prevalence of chronic conditions such as cancer, diabetes, and genetic disorders has escalated the demand for personalized treatment approaches.

AI, in particular, offers transformative potential by enabling more accurate diagnoses, optimized treatment selection, and advanced disease prediction. By tailoring treatment plans to individual patient profiles encompassing genetic information, disease stage, and medical history, AI contributes to better patient outcomes and reduces healthcare costs by focusing on the most effective therapies for each individual.

The implementation of AI, IoT, big data analytics, and blockchain advanced technologies significantly boosts operational efficiency. AI-driven systems automate numerous processes, minimize manual labor, and streamline workflows. In the pharmaceutical sector, AI is leveraged for tasks such as data analysis, documentation, and regulatory compliance, leading to cost savings and enhanced resource management. For instance, Starmind's AI-powered expertise directory facilitates efficient knowledge sharing and collaboration by connecting employees with internal experts, thereby reducing the time spent searching for information, keeping projects on track, and avoiding duplication of efforts by providing immediate access to verified expertise.

Blockchain technology plays a pivotal role in enhancing pharmaceutical operations by preventing counterfeit drugs, ensuring data integrity, and simplifying regulatory compliance. Its tamper-proof and transparent nature makes it exceptionally difficult for counterfeiters to infiltrate the supply chain. Enabling consumers to verify the authenticity of their medications through blockchain tracing allows them to make well-informed decisions regarding the products they use.

Pharmaceutical companies are investing in digital transformation initiatives, further accelerating market growth. Leading players are actively collaborating with technology providers to integrate AI, cloud computing, and advanced analytics into drug development and manufacturing processes. For instance, in March 2026, Eli Lilly expanded its partnership with Insilico Medicine in a deal valued at up to USD 2.75 billion to accelerate AI-driven drug discovery and pipeline development.

Global Pharma 4.0 Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Pharma 4.0 market report on the basis of type, technology, application, end use, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Software
• Services
• Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• AI &ML
• Big Data Analytics
• IoT
• Blockchain Technology
• Others (Digital twin, Advanced robotics, AR &VR)
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Drug Discovery & Development
• Manufacturing
• Supply Chain Management
• Others (Product Lifecycle Management, Personalized Medicine, Regulatory Compliance)
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Pharma & Biotech companies
• Healthcare Providers
• CMO (CONTRACT MANUFACTURING ORGANIZATION)
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Technology
  • 1.1.3. Application
  • 1.1.4. End Use
  • 1.1.5. Regional scope
  • 1.1.6. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Pharma 4.0 Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Digital transformation across the pharmaceutical value chain
    • 3.2.1.2. Growing adoption of AI and advanced analytics
    • 3.2.1.3. Rising complexity of drug development pipelines
    • 3.2.1.4. Increasing investments in smart manufacturing and automation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Implementation and Capital Investment Costs
    • 3.2.2.2. Data Integration and Interoperability Challenges
• 3.3. Pharma 4.0 Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Emerging Technologies

Chapter 4. Pharma 4.0 Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Pharma 4.0 Market by Type Outlook
• 4.4. Software
  • 4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.5. Services
  • 4.5.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Pharma 4.0 Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Pharma 4.0 Market by Technology Outlook
• 5.4. AI & ML
  • 5.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.5. Big Data Analytics
  • 5.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.6. IoT
  • 5.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.7. Blockchain Technology
  • 5.7.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.8. Others (Digital twin, Advanced robotics, AR &VR)
  • 5.8.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Pharma 4.0 Market: Application Estimates & Trend Analysis

• 6.1. Application Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Pharma 4.0 Market by Application Outlook
• 6.4. Drug Discovery & Development
  • 6.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 6.5. Manufacturing
  • 6.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 6.6. Supply Chain Management
  • 6.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 6.7. Others (Product Lifecycle Management, Personalized Medicine, Regulatory Compliance)
  • 6.7.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Pharma 4.0 Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2025 & 2033
• 7.2. Segment Dashboard
• 7.3. Global Pharma 4.0 Market by End Use Outlook
• 7.4. Pharma & Biotech companies
  • 7.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 7.5. Healthcare Providers
  • 7.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 7.6. CMO (CONTRACT MANUFACTURING ORGANIZATION)
  • 7.6.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 8. Pharma 4.0 Market: Regional Estimates & Trend Analysis, By Type, Technology, Application, and End Use

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Key company market share analysis, 2025
• 9.4. Company Profiles
  • 9.4.1. Microsoft
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. IBM
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Amazon Web Service Inc.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. SAP
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Oracle
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. GE Healthcare
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Siemens Healthineers
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Cisco Systems, Inc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Cinntra
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Dassault Systemes
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Nexocode
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives